guanfacine has been researched along with Benign Psychomotor Epilepsy, Childhood in 1 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Swartz, BE | 1 |
Kovalik, E | 1 |
Thomas, K | 1 |
Torgersen, D | 1 |
Mandelkern, MA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects[NCT01600885] | 16 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Scans will be analyzed for task-related prefrontal activation~Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline)" (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
Intervention | percent change in saline signal (Mean) |
---|---|
Guanfacine | -0.17 |
Placebo | -0.094 |
Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
Intervention | percent change in saline signal (Mean) |
---|---|
Guanfacine | -0.1 |
Placebo | 0.052 |
Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
Intervention | percent change in saline signal (Mean) |
---|---|
Guanfacine | -0.134 |
Placebo | -0.086 |
1 trial available for guanfacine and Benign Psychomotor Epilepsy, Childhood
Article | Year |
---|---|
The effects of an alpha-2 adrenergic agonist, guanfacine, on rCBF in human cortex in normal controls and subjects with focal epilepsy.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Blood Pressure; Cerebral Cor | 2000 |